ABLAVAR™ (formerly named Vasovistâ„¢) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVARâ„¢ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.

WARNING:
NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.

This dose means the RF power absorbed per unit of mass of an object, and is measured in watts per kilogram (W/kg).
The absorbed dose is dependent on the duty cycle and transmitter-coil type and increases with field strength, radio frequency power and and body size.
The specific absorption rate (SAR) describes the potential for heating of the patient's tissue due to the application of the RF energy necessary to produce the MR signal.

See also Specific Absorption Rate, MRI Safety, and MRI Risks.

Any abnormal reaction of a patient to an examination or procedure, like for example claustrophobia or side effects of MRI contrast agents.
A claustrophobic attack is MRI scanner dependent and more rare with an open MRI. An adverse reaction with magnetic resonance imaging contrast medium is very infrequent. In general, adverse reactions increase with the quantity of contrast media (usual dose of paramagnetic contrast agents is 0.1 mmol/kg) and also with the osmolarity of the compound.
Most frequently encountered adverse reactions are heat sensation, dizziness, nausea, hypotension due to vasodilatation, which can progress to hypotensive shock and anaphylactic reactions.
See also MRI Safety, Contrast Enhanced MRI, Breast MRI, and Cardiac MR imaging.

The brain tissue is provided with a tight endothelial layer on vessels that acts as a filter for substances that reach the brain through the blood stream. This filter is called the blood brain barrier.
The blood brain barrier is responsible for the absence of contrast agent enhancement in normal brain tissue after administration of the iodinated or paramagnetic contrast media used in brain MRI and computed tomography (CT) diagnostic. The absence of contrast uptake in normal tissue provides the basis for differentiation from pathological brain tissue, which is conversely characterized by a disruption of the blood brain barrier.

See also Contrast Enhanced MRI, MRI Safety, Adverse Reaction.

A pacemaker is a device for internal or external battery-operated cardiac pacing to overcome cardiac arrhythmias or heart block. All implanted electronic devices are susceptible to the electromagnetic fields used in magnetic resonance imaging. Therefore, the main magnetic field, the gradient field, and the radio frequency (RF) field are potential hazards for cardiac pacemaker patients.
The pacemaker's susceptibility to static field and its critical role in life support have warranted special consideration. The static magnetic field applies force to magnetic materials. This force and torque effects rise linearly with the field strength of the MRI machines. Both, RF fields and pulsed gradients can induce voltages in circuits or on the pacing lead, which will heat up the tissue around e.g. the lead tip, with a potential risk of thermal injury.
Regulations for pacemakers provide that they have to switch to the magnet mode in static magnetic fields above 1.0 mT. In MR imaging, the gradient and RF fields may mimic signals from the heart with inhibition or fast pacing of the heart. In the magnet mode, most of the current pacemakers will pace with a fix pulse rate because they do not accept the heartsignals. However, the state of an implanted pacemaker will be unpredictable inside a strong magnetic field. Transcutaneous controller adjustment of pacing rate is a feature of many units. Some achieve this control using switches activated by the external application of a magnet to open/close the switch. Others use rotation of an external magnet to turn internal controls. The fringe field around the MRI magnet can activate such switches or controls. Such activations are a safety risk.
Areas with fields higher than 0.5 mT (5 Gauss Limit) commonly have restricted access and/or are posted as a safety risk to persons with pacemakers.

A Cardiac pacemaker is because the risks, under normal circumstances an absolute contraindication for MRI procedures.
Nevertheless, with special precaution the risks can be lowered. Reprogramming the pacemaker to an asynchronous mode with fix pacing rate or turning off will reduce the risk of fast pacing or inhibition. Reducing the SAR value reduces the potential MRI risks of heating. For MRI scans of the head and the lower extremities, tissue heating also seems to be a smaller problem. If a transmit receive coil is used to scan the head or the feet, the cardiac pacemaker is outside the sending coil and possible heating is very limited.